国际妇产科学杂志

国际妇产科学杂志 ›› 2017, Vol. 44 ›› Issue (2): 142-145.

• 综述 • 上一篇    下一篇

交叉反应物质197在卵巢癌耐药中的研究进展

陈鑫玥，汤小晗，卢美松   

  1. 50001  哈尔滨医科大学附属第一医院妇产科
  • 收稿日期:2016-11-17 修回日期:2017-02-04 出版日期:2017-04-15 发布日期:2017-05-18
  • 通讯作者: 卢美松，E-mail: lumeisong0417@163.com E-mail:lumeisong0417@163.com
  • 基金资助:
    国家自然科学基金（81572551）

Progress in the Research of Cross-reacting Material 197 in Drug-resistant Ovarian Cancer

CHEN Xin-yue，TANG Xiao-han，LU Mei-song   

  1. Department of Obstetrics and Gynecology，The First Affiliated Hospital of Harbin Medical University，Harbin 150001，China
  • Received:2016-11-17 Revised:2017-02-04 Published:2017-04-15 Online:2017-05-18

PDF (PC)

6942

摘要：  卵巢癌起病隐匿，多数晚期卵巢癌患者会出现复发及对常规化疗耐药现象，严重威胁女性的生命健康。因此，化疗耐药已成为治愈卵巢癌的关键制约因素。肝素结合表皮生长因子（HB-EGF）作为表皮生长因子家族成员，已经被证实是一种有前景的卵巢癌化疗靶点。交叉反应物质197（cross-reacting material 197，CRM197）是一种无毒的白喉毒素变异体，特异性结合并抑制HB-EGF，从而抑制卵巢癌化疗耐药。研究表明，CRM197在多种肿瘤治疗及卵巢癌耐药方面均有显著作用，但是关于CRM197参与卵巢癌耐药的具体机制仍有待进一步研究。本文系统性描述CRM197的特性，并讨论CRM197在肿瘤治疗中的应用及CRM197与顺铂、紫杉醇联合应用在卵巢癌耐药中的研究进展。
   

关键词:  交叉反应物质197, 表皮生长因子, 卵巢肿瘤, 抗药性, 肿瘤, 顺铂, 紫杉酚

Abstract: Insidious onset of ovarian cancer, most advanced-stage patients with ovarian cancer relapse and become refractory to conventional chemotherapy，seriously threatening the lives and health of female. Therefore, a critical restrictor to cure ovarian cancer is the development of chemoresistance. Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF family of growth factors, has been proven to be a promising chemotherapeutic target for ovarian cancer. Cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin, which could inhibit the chemoresistance of ovarian cancer through binding and inhibiting to HB-EGF specifically. Studies have indicated that CRM197 has a significant role in the treatment of multiple tumors and the chemoresistance of ovarian cancer, but the specific mechanisms remain to be further studied in drug-resistant ovarian cancer. The feather of CRM197 will be reviewed. We will also discuss the application of CRM197 in tumor therapy and the research progress that the combination of paclitaxel and cisplatin with CRM197 in paclitaxel- and cisplatin-resistant ovarian cancer.
 

Key words: Cross-reacting material 197, Epidermal growth factor, Ovarian neoplasms, Drug resistance, neoplasm, Cisplatin, Paclitaxel